Scholar Rock Competitors and Similar CompaniesClear all
Scholar Rock's competitors and similar companies include Genentech, Livzon Pharmaceutical Group and Biogen.
 Scholar Rock Scholar Rock is discovering and developing a new class of biologic therapies to selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation, resulting in therapeutic effects specifically at the source of disease. |  Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. |  Livzon Pharmaceutical Group Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | |
Founding Date | Founding Date 2012 | Founding Date 1976 | Founding Date 1985 | Founding Date 1978 |
Type | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ Cambridge, US | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more | Locations Zhuhai, CN HQ Chengdu, CN Qingyuan, CN Shanghai, CN Shaoguan, CN Shenzhen, CN Zhuhai, CN | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 1401% increase | Employees 18,077 | Employees 9,067 | Employees 7,605 |
Valuation ($) | Valuation ($) 2.8 b | Valuation ($) N/A | Valuation ($) 4.2 b | Valuation ($) 26.7 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥11.7b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥4.1b (FY, 2025) | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥7.8b (FY, 2025) | Gross profit $7.5b (FY, 2025) |
Net income | Net income ($377.9m) (FY, 2025) | Net income N/A | Net income ¥2.4b (FY, 2025) | Net income $1.3b (FY, 2025) |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 28 (Jul, 2025) | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2024) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 19 (Jul, 2025) | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 41 (Jul, 2025) | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
Genentech
HQ
South San Francisco, US
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
View companyLivzon Pharmaceutical Group
HQ
Zhuhai, CN
Employees
9,067
Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company